Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001829126-22-019258
Filing Date
2022-11-14
Accepted
2022-11-14 16:31:00
Documents
52
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q titanpharma_10q.htm   iXBRL 10-Q 574957
2 EXHIBIT 10.1 titanpharma_ex10-1.htm EX-10.1 50850
3 EXHIBIT 10.2 titanpharma_ex10-2.htm EX-10.2 151674
4 EXHIBIT 31.1 titanpharma_ex31-1.htm EX-31.1 11203
5 EXHIBIT 32.1 titanpharma_ex32-1.htm EX-32.1 5319
  Complete submission text file 0001829126-22-019258.txt   3445194

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ttnp-20220930.xsd EX-101.SCH 24181
7 XBRL CALCULATION FILE ttnp-20220930_cal.xml EX-101.CAL 41605
8 XBRL DEFINITION FILE ttnp-20220930_def.xml EX-101.DEF 89176
9 XBRL LABEL FILE ttnp-20220930_lab.xml EX-101.LAB 228058
10 XBRL PRESENTATION FILE ttnp-20220930_pre.xml EX-101.PRE 178801
46 EXTRACTED XBRL INSTANCE DOCUMENT titanpharma_10q_htm.xml XML 467575
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-13341 | Film No.: 221386386
SIC: 2836 Biological Products, (No Diagnostic Substances)